Go to navigation Go to content
Toll-Free: (888) 606-5297
Phone: (859) 578-4444
Schachter, Hendy & Johnson, Attorneys At Law

Is Virility Worth the Risk of Testosterone Therapies Like AndroGel?

Comments (0)

There is a certain inevitability about the recent finding that testosterone replacement therapy (TRT), such as AndroGel and Androderm, poses the same risk to cardiovascular health as hormone replacement therapy (HRT) does in women. A new study now gives evidence that testosterone replacement is associated with an increased risk of stroke and heart attack.

There is no evidence that gradually declining levels of testosterone in men as they age is anything other than normal. Despite this reality, prescriptions for testosterone therapy have rocketed. Annual prescriptions for testosterone in the US increased more than five-fold from 2000 to 2011, reaching 5.3 million prescriptions and a market of $1.6 billion in 2011.

As far as testosterone therapy is concerned, large randomised controlled trials are now required to exactly define the risk of testosterone therapy across all age groups, including a growing number of young men who use testosterone for the purpose of physical enhancement.

But already there is a strong case for caveat emptor: enhanced virility may be achievable but at what cost?

If a loved one died after using testosterone therapy or if you or a loved one suffered a heart attack or stroke after undergoing testosterone therapy, please call our office for a free consultation.

Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."


Email:* (will not be published)


Notify me of follow-up comments via email.

Live Chat